Does PRP Help Tennis Elbow? What Clinical Trials Show
- Updated November 14, 2026
- Stop 1 of 4 on the PRP injections line
When platelet-rich plasma (PRP) is compared with a placebo injection, it does not clearly help. A 2026 meta-analysis of six randomized placebo-controlled trials (355 patients) found PRP was not statistically better than placebo for pain or function at 4 weeks, 8 to 12 weeks, or 24 to 26 weeks. Studies comparing PRP with steroid injections answer a different question and can look more favorable to PRP. A non-significant result does not prove PRP has exactly zero effect for every preparation, but the placebo evidence does not support it as a proven treatment.
What is tennis elbow, and who was studied?
Tennis elbow, or lateral epicondylitis, is pain on the outer side of the elbow where the forearm muscles that extend the wrist attach to bone. It is also called lateral elbow tendinopathy, reflecting the view that it is a load-related tendon problem; the terminology is explained in tendinitis vs. tendinosis. It usually causes pain with gripping, lifting or wrist extension.
The trials in the placebo meta-analysis enrolled adults with clinically diagnosed lateral epicondylitis. Other causes of outer elbow pain, such as nerve compression, joint problems or pain referred from the neck, need to be considered by a clinician before the label is applied.
Why has PRP been investigated?
PRP concentrates platelets from your own blood. Platelets release growth factors involved in normal tissue repair, so the hypothesis is that injecting a concentrated dose into a painful tendon might support healing. That hypothesis is reasonable to test. It has not been shown that PRP repairs the tendon in people with tennis elbow, which is why placebo-controlled trials matter.
PRP versus placebo: what do randomized studies show?
The key study is a meta-analysis in The American Journal of Sports Medicine (volume 54, issue 5, PubMed abstract), published online January 8, 2026, titled “Platelet-Rich Plasma Does Not Improve Pain or Function in Patients With Lateral Epicondylitis as Compared With Placebo.” It pooled six randomized trials with 355 patients that compared PRP with a placebo injection.
The published abstract reports the pooled estimates directly:
- Pain did not differ significantly between PRP and placebo at 4 weeks (standardized mean difference 0.08, 95% CI −0.17 to 0.34), 8 to 12 weeks (−0.36, 95% CI −0.99 to 0.27) or 24 to 26 weeks (mean difference −1.58, 95% CI −4.74 to 1.58).
- Function did not differ significantly at 4 weeks (0.09, 95% CI −0.18 to 0.37), 12 weeks (−0.09, 95% CI −0.39 to 0.21) or 24 to 26 weeks (0.13, 95% CI −0.18 to 0.43).
- Adverse events did not differ significantly between groups; the abstract reports a risk ratio of 1.66 with a wide 95% confidence interval of 0.65 to 4.19, so a difference in either direction cannot be ruled out.
Every confidence interval for pain and function crosses zero, which is why the authors concluded that their findings do not support PRP as a recommended treatment for this condition. The abstract does not name the specific pain and function scales, so the −1.58 figure cannot be translated into points a patient would notice; what can be read from it is that the interval includes no difference. Secondary write-ups of the same study, from OrthoEvidence and Healio’s coverage of its conference presentation, report the same direction of results.
This is consistent with earlier work. A 2020 meta-analysis of five placebo-controlled trials (276 participants), published in Clinical Rheumatology, and a 2022 guideline’s meta-analysis of nonsurgical treatments also found PRP similar to placebo on pain and function. The 2020 authors noted that patients reported improvement after both PRP and placebo injections, which is why uncontrolled reports of improvement after PRP are hard to interpret.
A different 2026 review is sometimes cited alongside it and should not be confused with it. That review pooled 10 randomized trials with 615 participants to look at complications, and it included corticosteroid, saline, hyaluronic acid and whole-blood comparators. Its abstract reports no significant difference in complications between PRP and corticosteroid or saline in the meta-analysis. When all comparison groups were combined, complications were more frequent with PRP (14.77% vs. 9.46%), mainly because of post-injection pain, and the rates were comparable once pain was excluded. No severe complications were reported. Its different inclusion criteria explain why its trial count differs; it is a safety synthesis, not an updated placebo efficacy analysis.
For the 2026 placebo meta-analysis, the abstract reports the pooled estimates given above; the names of the pain and function scales and the study-level details require the full paper.
PRP versus corticosteroid or other injections: why might results differ?
| Comparison | What it tests | Typical pattern in the literature | Why it cannot answer the placebo question |
|---|---|---|---|
| PRP vs. saline or other placebo | Whether PRP does anything beyond the injection itself and time | No significant difference in the 2026 pooled analysis | This is the placebo question |
| PRP vs. corticosteroid | Which of two active injections does better over time | Steroid often looks better early, PRP sometimes looks better later | If steroid helps briefly and then symptoms return, PRP can look "better" later without beating placebo |
| PRP vs. other injections (autologous blood, hyaluronic acid, others) | Relative performance among treatments | Mixed | Neither arm is a placebo |
The middle row explains why reviews can seem to disagree. Reviews comparing PRP with steroid have reported faster early relief with steroid and slower, longer-lasting improvement with PRP. A 2018 systematic review in SICOT-J described that pattern. But a treatment can outperform steroid at six months and still not outperform placebo, if steroid’s early benefit fades. So a steroid comparison cannot settle whether PRP itself works.
What about rehabilitation and exercise-based care?
Initial care for tennis elbow can include activity modification, time, and exercise-based physical therapy guided by a clinician, along with symptom relief. The same 2022 guideline analysis cited above included exercise-based physiotherapy among the nonsurgical options it reviewed. Persistent symptoms, weakness, numbness, or pain that does not fit the usual pattern are reasons for further evaluation rather than another injection.
What remains uncertain?
- Formulation. Platelet concentration and white blood cell content vary between products. A 2025 meta-regression suggested platelet dose might explain some differences between trials, but that is a hypothesis to test, not an established rule.
- Number of injections. The placebo data do not establish whether a different number of injections would change the result.
- Patient selection. It is unknown whether some subgroups respond differently.
- Long-term outcome. The placebo trials pooled through about six months.
Safety details for PRP, including how elbow and knee data differ, are in the risks and side effects of PRP injections.
Is PRP proven to be better than placebo for tennis elbow? No. The 2026 placebo-controlled meta-analysis found no significant advantage for pain or function at any of its assessed time points.
Does a steroid comparison settle the question? No. Beating steroid at a later time point is not the same as beating placebo.
Every stop on the PRP injections line
- Does PRP Help Tennis Elbow? What Clinical Trials Show
- PRP for Achilles Tendinopathy: What Does the Evidence Say?
- PRP vs. Hyaluronic Acid Injections for Knee Osteoarthritis: What Does Research Show?
- What Are the Risks and Side Effects of PRP Injections?
Leave a note on this stop